KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Finished Goods: 2010-2018

Historic Finished Goods for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Dec 2018 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Finished Goods fell 0.89% to $2.7 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 billion, marking a year-over-year decrease of 0.89%. This contributed to the annual value of $2.7 billion for FY2018, which is 0.89% down from last year.
  • Teva Pharmaceutical Industries' Finished Goods amounted to $2.7 billion in FY2018, which was down 0.89% from $2.7 billion recorded in FY2017.
  • Teva Pharmaceutical Industries' 5-year Finished Goods high stood at $2.8 billion for FY2016, and its period low was $2.0 billion during FY2015.
  • In the last 3 years, Teva Pharmaceutical Industries' Finished Goods had a median value of $2.7 billion in 2017 and averaged $2.7 billion.
  • Its Finished Goods has fluctuated over the past 5 years, first fell by 11.65% in 2014, then skyrocketed by 38.15% in 2016.
  • Teva Pharmaceutical Industries' Finished Goods (Yearly) stood at $2.3 billion in 2014, then dropped by 9.61% to $2.0 billion in 2015, then skyrocketed by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then decreased by 0.89% to $2.7 billion in 2018.